Celldex Therapeutics, Inc. (CLDX) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello. Welcome to CELF-DEX conference call and webcast. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask the question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. I would now like to turn the conference over to Sarah Kavanagh. You may begin. Thank you. Good evening, and thank you all for joining us to discuss the latest results from our Phase 2 Barzavolumab Program in Chronic Spontaneous Cuticaria, or CSU, which are being presented tomorrow morning in a late-breaking oral presentation at the European Academy of Allergy and Clinical Immunology Congress in Glasgow, Scotland. The embargo on the study listed at the start of the call, and this evening we will be discussing the data set in full. Joining me on the call today are Anthony Marucci, Co-Founder, President, and Chief Executive Officer, Dr. Tibor Keller, Co-Founder, Executive Vice President, and Chief Scientific Officer, Dr. Diane Young, Senior Vice President and Chief Medical Officer, and Dr. Margot Hicciozzi, Senior Vice President of Regulatory Affairs. We are also very pleased to be joined by Dr. Martin Metz, Professor, Department of Dermatology and Allergy, Head of Translational Research, and Deputy Head of Clinical Trials at Charité University in Berlin. and the lead investigator for this study. Doctors Yang and Metz are joining us quite late from separate locations in Europe, and I really appreciate that. Please note the slides for tonight's call are available on the Investor Relations section of our website. Tomorrow at 4.12 a.m., when the oral presentation begins, t...